A phase I/II study of NED-170 for Cancer
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs NED-170 (Primary)
- Indications Breast cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- 17 Oct 2019 According to a NED Biosystems media release, the company plans to initiate the study in 2020
- 29 Apr 2019 According to a NED Biosystems media release, the company is finalizing the protocol for a phase I/IIA clinical trial to investigate the safety and efficacy of NED-170 in 10 patients with treatment-refractory triple-negative breast cancer and 10 with refractory cholangiocarcinoma. The company expects to begin enrollment in the second half of 2019.
- 12 Feb 2019 According to a NED Biosystems media release, this study is expected to initiate by 1H 2019.